Cuevas VS, Higareda GRA, Mogollón FR, Godínez ÁP, Campuzano VS, Takahashi ÁTJE

Language: Spanish
References: 11
Page: 1-9
PDF size: 342.86 Kb.

ABSTRACT

Case description: Three pediatric patients with urethral stenosis due to multiple etiologies underwent mechanical Paclitaxel coated balloon dilation (Ranger TM). All of them underwent fluoroscopic follow-up at 3 months and no recurrence was observed.
Relevance: The worldwide incidence of urethral stenosis in males is 0.2- 0.6 %. Currently, urethroplasty is the best therapeutic option. Paclitaxel is an antiproliferative drug initially used as a chemotherapeutic agent and currently used for resolution of coronary obstruction due to the inhibition of fibroblast growth. We advocate for its use along with mechanical ballon dilation for the treatment of urethral stenosis.
Clinical implications: Urethral Paclitaxel balloon dilation has shown better anatomic and functional results in anterior urethral stenosis compared with endoscopic treatment, specially in recurrent stenosis <3 cm in third fase studies. The short and medium term results are promising with a success rate of more than 65 %.
Conclusions: Paclitaxel coated balloon dilation can be used safely in pediatric patients with urethral stenosis, achieving resolution of obstruction.

REFERENCES

1. Santucci RA, Joyce GF, Wise M. Male UrethralStricture Disease. The Journal of Urology. 2007;https://doi.org/10.1016/j.juro.2007.01.041.

2. Barratt R, Chan G, La Rocca R, DimitropoulosK, Martins FE, Campos-Juanatey F, et al.Free Graft Augmentation Urethroplasty forBulbar Urethral Strictures: Which Technique IsBest? A Systematic Review. European Urology.2021;80(1): 57–68. https://doi.org/10.1016/j.eururo.2021.03.026.

3. Bullock TL, Brandes SB. Adult AnteriorUrethral Strictures: A National Practice PatternsSurvey of Board Certified Urologists in theUnited States. The Journal of Urology. 2007;https://doi.org/10.1016/j.juro.2006.09.052.

4. Anger JT, Buckley JC, Santucci RA, ElliottSP, Saigal CS. Trends in Stricture ManagementAmong Male Medicare Beneficiaries: Underuseof Urethroplasty? Urology. 2011;77(2): 481–485.https://doi.org/10.1016/j.urology.2010.05.055.

5. Wessells H, Angermeier KW, Elliott S,Gonzalez CM, Kodama R, Peterson AC,et al. Male Urethral Stricture: AmericanUrological Association Guideline. The Journalof Urology. 2017;197(1): 182–190. https://doi.org/10.1016/j.juro.2016.07.087.

6. Steenkamp JW, Heyns CF, de Kock ML. Internalurethrotomy versus dilation as treatmentfor male urethral strictures: a prospective,randomized comparison. The Journal of Urology.1997;157(1): 98–101.

7. Santucci R, Eisenberg L. Urethrotomy hasa much lower success rate than previouslyreported. The Journal of urology. 2010;183(5).https://doi.org/10.1016/j.juro.2010.01.020.

8. Pansadoro V, Emiliozzi P. Internal urethrotomyin the management of anterior urethralstrictures: long-term followup. The Journal ofurology. 1996;156(1). https://pubmed.ncbi.nlm.nih.gov/8648841/

9. Elterman DS, Coutinho K, Hagedorn JC. HowI Do It: The Optilume drug-coated balloon forurethral strictures. The Canadian Journal ofUrology. 2020;27(4): 10322–10328.

10. Virasoro R, DeLong JM, Estrella RE, Pichardo M,Rodriguez Lay R, Espino G, et al. A Drug-CoatedBalloon Treatment for Urethral Stricture Disease:Three-Year Results from the ROBUST I Study.Research and Reports in Urology. 2022;14: 177–183.https://doi.org/10.2147/RRU.S359872.

11. Elliott SP, Coutinho K, Robertson KJ, D’Anna R,Chevli K, Carrier S, et al. One-Year Results forthe ROBUST III Randomized Controlled TrialEvaluating the Optilume® Drug-Coated Balloonfor Anterior Urethral Strictures. The Journalof Urology. 2022; https://doi.org/10.1097/JU.0000000000002346.